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Abstract 
 
Background: The additional burden of HCV infection in HIV-HCV coinfected individuals 
may have some consequences on adherence to highly active antiretroviral therapy (HAART). 
Few studies have explored the pattern of correlates of non-adherence to HAART while 
simultaneously considering the impact of HCV treatment and depressive symptoms on 
adherence to HAART. We used longitudinal data to assess factors associated with non-
adherence to HAART. Methods: The French national prospective cohort ANRS-CO-13-
HEPAVIH is a multi-center cohort which recruited 1175 HIV-HCV coinfected patients in 17 
hospital outpatient units delivering HIV and HCV care in France between October 2006 and 
June 2008. For this analysis, we selected participants on HAART with self-reported data for 
adherence to HAART (n = 727 patients, 1190 visits). Data were collected using self-
administered questionnaires and medical records. A mixed logistic regression model based on 
an exchangeable correlation matrix was used to identify factors associated with non-
adherence to HAART. Results: Patients reported non-adherence to HAART in 808 (68%) of 
the 1190 visits. Four variables remained associated with non-adherence to HAART after 
multivariate analysis: hazardous alcohol consumption, cocaine use and depressive symptoms, 
regardless of whether treatment for depression was being received. Finally, patients being 
treated for HCV infection were less likely to be non-adherent to HAART. Conclusions: 
Besides the problem of polydrug use, two other dimensions deserve special attention when 
considering adherence to HAART in HIV-HCV coinfected patients. Access to HCV treatment 
should be encouraged as well adequate treatment for depression in this population to improve 
adherence and response to HAART. 
Key words: adherence, coinfection, depressive symptoms, HIV, HCV, treatment. 
Introduction 
 
Adherence to highly active antiretroviral therapy (HAART) is a crucial aspect of medical care 
in HIV infected patients and has been widely investigated [1, 2]. Many factors have been 
identified as potential determinants of non-adherence to HAART among monoinfected HIV 
patients, including medical factors related to care and treatment [3] and non-medical factors 
such as socio-economic, behavioral and structural determinants e.g. incarceration [4, 5]. The 
identification of these factors has led to the development of a multidisciplinary approach 
towards improving adherence to HAART, wherein new interventions to tackle these factors 
are continuously incorporated. [6]. Part of this approach is to provide improved mental 
healthcare services for HIV infected persons, the main reason being that psychiatric 
comorbidities are often associated with chronic diseases [7] in this population [8]. Moreover, 
mental health and depressive symptoms have a large impact on adherence to HAART [9] and 
have been the subject of many studies exploring effective clinical strategies to prevent or treat 
depression [10, 11].  
In HIV-HCV coinfected patients, HCV infection seems to be an independent factor associated 
with poorer adherence to HAART [12]. In addition, the burden of depression is a challenging 
concern for HIV clinicians as HIV-HCV individuals are characterized by more severe 
depression than are their HIV monoinfected counterparts [13]. Moreover, a recent study has 
shown the first evidence of an association between chronic HCV and recurrent brief episodes 
of depression, independent of HCV treatment (IFN-alpha) and substance or alcohol abuse 
[14]. HCV treatment initiation is known to induce depressive symptoms independently of any 
inherent patient susceptibility to major depression [15]. Besides the fear of HCV treatment 
inducing depressive symptoms in coinfected individuals, there is also the worry that it may 
have a negative impact of adherence to HAART in this population. This fear was expressed 
during the most recent IAS conference [16]. 
The ANRS CO13 HEPAVIH cohort gave us the opportunity to explore the impact of HCV 
treatment, depressive symptoms and antidepressant treatment on adherence to HAART in a 
cohort of HIV-HCV coinfected patients.  
 
Methods 
 
Study design 
 
The French ANRS-CO13-HEPAVIH cohort was designed to study the clinical, 
immunological, virological, and socio-behavioral course of HIV-HCV coinfected individuals. 
This longitudinal study recruited 1175 HIV-HCV coinfected individuals in 17 outpatient 
hospital units delivering care to HIV and HCV positive individuals in France between 
October 2006 and June 2008 and monitored them for 60 months [17]. 
Individuals enrolled had to be HIV-positive with chronic HCV infection. Those with 
sustained virological response (undetectable HCV viral load for more than 6 months after 
treatment for HCV) were not included. Patients who agreed to participate signed a letter of 
informed consent and were given a self-administered questionnaire at every annual visit 
(visits were annual) that included items on socio-demographic characteristics, past and current 
drug and alcohol use, treatment history, HAART adherence and psychosocial factors. 
Clinical and biological data, including HIV viral load, CD4 count and liver fibrosis stage, 
were evaluated using a different questionnaire given to each clinical center’s medical staff.  
The study was approved by a French institutional review board. 
 
Study population 
 
Among the 1175 patients included in the cohort, individuals with decompensated cirrhosis, 
those who had undergone a liver transplantation, those who had hepatocellular carcinoma and 
those who had been cured of their HCV infection were initially excluded. Of the remaining 
1021 patients, only those receiving HAART (n=954) and whose data on adherence to 
HAART and on depressive symptoms were available for at least one visit (n=727) -
accounting for 1190 visits - were included in the analyses.  
  
Questionnaires 
 
Self-administered questionnaires 
The self-administered questionnaires collected psychosocial and behavioral characteristics at 
enrolment and at each follow-up visit. They consisted of several sections accounting for 
approximately 100 items focusing on socio-demographic characteristics, history of drug use, 
addictive behaviors, adherence to HAART, side effects and depressive symptoms. 
Demographic information and details about educational level, employment and housing were 
also collected. For history of drug use and current drug and alcohol use, we documented the 
year of first drug injection. Each patient’s history of substance use was assessed using the 
Addiction Severity Index (ASI) [18], the substances included for assessment being cannabis, 
cocaine, heroin, crack, ecstasy, buprenorphine, methadone, amphetamines and hallucinogens.  
Alcohol consumption was measured using the AUDIT-C questionnaire. Hazardous alcohol 
consumption was defined as a score ≥ 4 for men and ≥ 3 for women [19].  
Data about patients' perceptions of treatment side effects were collected using a section in the 
questionnaires exploring the occurrence of 39 symptoms over the previous four weeks, and 
the discomfort these symptoms had caused. This section was based on the Symptoms Distress 
Module proposed by Justice et al. [20] which lists symptoms known to occur while on 
HAART. It was broadened to include questions on lipodystrophy symptoms and symptoms 
associated with interferon-based therapy. 
Patients' depressive symptomatology was assessed using the Center for Epidemiological 
Studies Depression scale (CES-D) [21]. Patients' feelings and behaviors over the previous 
week were used to calculate a global depression score ranging from 0 to 60. The cut-off points 
17 and 23 for men and women, respectively, were chosen as indicative of depressive 
symptoms (DS) [22]. This variable was then combined with the information about use of 
antidepressant treatment(s) (ADT) during the previous 6 months in order that patients could 
be classified according to the following categories: “no depressive symptoms and no ADT” 
(which was used as the reference group in the analysis), “no depressive symptoms and ADT”, 
“depressive symptoms and no ADT” and “depressive symptoms and ADT”. 
 
Measurement of adherence to HAART 
In the self-administered questionnaire, a set of seven questions was used to assess adherence 
to HAART. At each clinical visit, all HAART-treated patients were asked to list, for each 
antiretroviral drug, the daily number of prescribed pills they had taken during the four days 
prior to that particular visit. They were also asked if they had “totally” or “partially” taken 
their prescribed doses of HAART or had “interrupted their treatment” during the same 4-day 
period. Patients were considered non-adherent if they reported that they had taken <100% of 
the total dose of antiretroviral drugs prescribed, and/or if they had not totally followed their 
prescribed regimen during the 4-day period prior to that particular visit. In addition, the visual 
analogue scale was used to reclassify those patients whose scale score was <100% as non-
adherent. In other words, a patient who reported that he/she was adherent in all previous 
questions in the adherence section was nonetheless reclassified as non-adherent if he/she 
reported a score different from 100% in the visual analog scale (from 1 to 6). This approach 
has been previously validated using protease inhibitor dosage measurement via urine analysis 
[23]. 
 
Medical questionnaire 
A medical questionnaire at enrolment collected retrospective data about the patient’s history, 
including clinical and biological data (HIV viral load, CD4 count, and liver fibrosis stage 
based on Metavir score, and provided either by biopsy, transient elastometry  (Fibroscan™) or 
FibroTest™ results), together with other data on treatment history, including HAART 
regimen and HCV treatment. 
 
Statistical analysis 
 
Analyses were performed for the 727 coinfected patients (accounting for 1190 visits) who 
were receiving HAART and who had available data on both depressive symptoms and 
adherence to HAART. Clinical and psychosocial characteristics of patients, including depres-
sive symptoms, access to HCV therapy, self-reported treatment-related side effects, and drug 
and alcohol use were tested for their association with adherence to HAART. 
To identify factors associated with non-adherence to HAART, we used a mixed logistic 
regression based on an exchangeable correlation matrix. To avoid situations where strong 
confounding could have hidden important predictors of non-adherence, a liberal p-value of 
<0.20 in the univariate analyses was chosen to define the variables to be entered into the 
selection procedure for the multivariate model. A step-by-step backward procedure based on 
the log-likelihood ratio test was used to identify the variables, with a p-value of <0.05, in the 
multivariate model. 
The association between “depressive symptoms and anti-depressant treatment” and two other 
variables, “the number of perceived symptoms” and “daily cannabis use”, was also tested.  
 
Results 
 
Descriptive analysis 
 
First, no significant difference was found between participants included in the analyses and 
those who were not, in terms of socio-demographic and clinical characteristics. 
The baseline characteristics of the 727 patients included in the analyses are described in 
Table 1.  
From a total of 1190 visits, 296 patients (808 visits, 68% of the 1190 visits) reported being 
non-adherent to HAART, 346 patients (484 visits, 41%) had depressive symptoms and 196 
patients (261 visits, 22%) reported having received ADT in the previous 6 months. 
Of the 484 visits where patients reported depressive symptoms, 238 patients (312 visits, 64%) 
were not being treated for their depression, while 136 patients (172 visits, 36%) were 
receiving ADT. Of the 706 visits where patients had no depressive symptoms, 421 patients 
(617 visits, 52%) were not being treated and 76 patients (89 visits, 7%) were receiving ADT. 
Hazardous alcohol consumption was reported by 286 patients (397 visits, 33%), daily 
cannabis use by 125 patients (171 visits, 16%), cocaine use by 78 patients (98 visits) and 
heroin use by 25 patients (32 visits, 3%). The median [IQR] number of self-reported side 
effects was 9[4-14]. 
Finally, 223 patients were receiving HCV therapy (354 visits, 30%). 
 Factors associated with non-adherence to HAART 
 
Univariate analysis 
Table 2 shows the crude and adjusted ORs of possible correlates of non-adherence to 
HAART. The variables which were eligible for the final model are indicated in bold. Some 
socio-demographic characteristics were found to be associated with adherence: Older patients, 
those who were employed, those living in a couple and those having comfortable housing 
were all less likely to be non-adherent to HAART. Certain behavioral and psychological 
outcomes influenced adherence to HAART in the univariate model: depressive symptoms, 
antidepressant treatment, daily alcohol consumption, daily cannabis use and cocaine use. 
Experience of progression to AIDS (CDC stage C) was found to be associated with adherence 
to HAART. Patients who were being treated for their HCV infection were more likely to be 
adherent to HAART.   
Two additional variables - the number of symptoms and daily cannabis use - were found to be 
correlates of non-adherence to HAART in the univariate analysis but were not included in the 
final model as they were collinear with “depressive symptoms and antidepressant treatment” 
which had a stronger association with the outcome. Tables 3 and 4 show the significant 
association between the DS/ADT variable and the number of symptoms or daily cannabis use. 
Even though the number of symptoms was associated with being treated with antidepressants 
without having any depressive symptoms, the strongest association (a greater than five-fold 
higher risk of perceiving depressive symptoms) was in patients who had depressive 
symptoms, whether they were being treated with antidepressants or not. However, daily 
cannabis use was associated only with those patients who had depressive symptoms while on 
antidepressant treatment.  
 Multivariate analyses 
The results show that, after multiple adjustments (Table 2), patients who reported hazardous 
alcohol consumption (OR[95%CI]=1.91[1.27-2.87], p=0.002) and cocaine use (OR[95%CI] 
=2.26[1.15-4.43], p=0.02) were significantly more likely to be non-adherent to HAART. 
Patients who reported depressive symptoms were also significantly less adherent to HAART, 
whether they were being treated for depression (OR [95%CI]= 1.83[1.05-3.22], p=0.03) or 
not (OR[95%CI]= 1.63[1.04-2.54], p=0.03). Finally, patients who were being treated for HCV 
infection were less likely to be non-adherent to HAART (OR[95%CI]=0.38 [0.17-0.84], 
p=0.02). 
 
Discussion 
 
The main results of this study suggest that HIV-HCV coinfected patients with depressive 
symptoms are at higher risk of non-adherence to HAART - whether they are on antidepressant 
treatment or not - and that being treated for HCV has a positive impact on adherence to 
HAART. Not surprisingly, we also found that cocaine use and alcohol consumption continue 
to be factors associated with non-adherence to HAART.  
In other words, the findings from this large cohort show that initiating HIV-HCV coinfected 
patients in HCV treatment may facilitate adherence to HAART. Indeed, it was important to 
adjust the multivariate model for this variable, as patients who were being treated for HCV 
infection were more likely to be adherent to HAART. Although this paper focuses more on 
the impact of depression and antidepressant treatment, the latter result deserves attention. It 
should be confirmed in a more specific study aimed at examining improved access to 
treatment for HCV in HIV-HCV coinfected population [24]. It is known that HIV-HCV 
coinfected patients face particular barriers to accessing HCV care. They are more often past or 
current drug users [25], have more chaotic lifestyles and are seen as people with disrupted 
lives who find it difficult to adhere to treatment [26].  
The main result of the present article concerns the impact of depressive symptoms on 
adherence to HAART. It is known that depression is very prevalent in HCV-infected people, 
whether receiving treatment for their HCV infection or not [27]. In addition, it has been 
shown that high rates of depressive symptoms are related to comorbidities such as HCV in 
such individuals [13]. Given the higher prevalence of depressive symptoms among HIV-HCV 
coinfected individuals [28] and the negative impact of these symptoms on adherence to 
HAART, optimizing clinical management of depression is crucial. As we expected, our 
results indicate that depressive symptoms are associated with non-adherence to HAART. This 
confirms the findings of a recent meta-analysis [29]. However, when we considered those 
who were receiving ADT, patients who had depressive symptoms while being treated had a 
higher risk of non-adherence to HAART than those who were not being treated with ADT. 
This important result may be a sign of inadequacy in the provision of care for depression in 
some HIV-HCV coinfected patients receiving HAART.  
Yun et al. have already demonstrated the positive impact of antidepressant treatment on 
adherence to HAART in HIV-infected depressed patients [30]. A previous analysis using the 
baseline data of Hepavih cohort showed that patients successfully treated for their depression 
exhibited similar levels of fatigue impact to those with no depressive symptoms and not 
taking antidepressant treatment [31]. However, the lack of ADT effectiveness, as indicated by 
persistent depressive symptoms, may be a sign of severe depression or treatment inadequacy. 
It would therefore seem important to diagnose depression early on and to treat it effectively in 
order to optimize HIV care. This is especially true with respect to improving adherence to 
HAART among HIV-HCV coinfected patients. 
In line with other reports [32, 33] the present study suggests that alcohol use interferes with 
adherence to HAART. The most worrying issue is that alcohol problems are more prevalent in 
the HCV-infected population [34] than in their non-HCV infected counterparts. Paying 
greater attention to heavy alcohol drinkers by proposing psychological and/or 
pharmacological responses would seem to be of great importance. For instance, some studies 
have shown interesting findings either using baclofen in HCV-infected patients [35] or 
behavioral counseling in HCV-infected IDU [36]. 
In this study, cocaine use was also found to be a factor associated with non-adherence to 
HAART. Although some studies have found mixed results concerning the negative impact of 
active drug use on adherence to HAART and viral suppression [37], cocaine use has already 
been shown to impair a positive response to HAART [38]. The only current therapy offered 
for cocaine abusers, based on the cognitive behavioral model, seems to be insufficient in 
terms of  reducing cocaine use [39]. New pharmacological responses to cocaine abuse and 
dependence are needed for HIV-HCV coinfected patients. Furthermore the development of 
agonist treatments for cocaine dependence would seem to be an interesting avenue of research 
to pursue for such HIV-HCV coinfected patients as the efficacy of opioid maintenance 
treatment in HIV-infected opioid dependent populations has already been proven [40, 41]. 
Regarding daily cannabis use, our results showed that patients reported daily cannabis use in 
16% of visits during follow-up. This behavior was found to be associated with non-adherence 
to HAART and had a strong association with having depressive symptoms and being treated 
with ADP. This group (17%) of patients had more severe depressive symptoms. Indeed, it is 
known that cannabis dependence may increase psychiatric comorbidities [42, 43] and 
depressive symptoms have been found to be higher in cannabis users [44]. Moreover, we also 
found that the higher the number of self-reported symptoms the higher the non-adherence to 
HAART. This is in line with previous studies that have demonstrated that reporting perceived 
side-effects decreased adherence to HAART [45]. However, many other studies have 
highlighted the relationship between depression and perceived symptoms such as pain or 
fatigue [46], suggesting that HCV-related somatic symptoms may be part of a causal pathway 
leading to depression. That is why treating depression in this population is important in order 
to improve adherence to HAART but also to alleviate HCV related symptoms. 
 
Some limitations of this study should be acknowledged. First, the reliability of self-reported 
adherence remains a concern. However, a meta-analysis has already demonstrated the validity 
of self-reported measures of adherence [47]. To control for social desirability bias, we used a 
high cut-off score and an algorithm reclassifying patients reporting non-adherence at least 
once in the adherence questionnaire as non-adherent. Second, the CES-D scale includes 
several items that measure somatic and physical symptoms of depression. One limitation of 
using this tool is that physical symptoms are not specific to depression. In depressed patients 
with HIV infection, certain symptoms such as loss of appetite, sleep disturbances, difficulty in 
concentration, fatigue, could be confounded with the physical symptoms of the underlying 
medical condition. However, as we adjusted the statistical model for HIV variables, any 
confounding effect of HIV symptoms should be limited. Moreover, the use of the CES-D 
scale to diagnose depression could be criticized because of its lack of clinical accuracy in 
terms of measuring major depression. Complementing it with other scales could, potentially, 
improve its screening power [48]. However, the CES-D scale still remains an appropriate tool 
for detecting depressive symptoms with gender-specific cut-off values [49]. Another 
limitation of this study is that we did not study adherence to ADT. Had we done so, we could 
have investigated whether the inefficacy of ADT among patients who reported depressive 
symptoms was due to poor ADT treatment adherence. 
 
Our results, which focus on depression management, highlight the need to take into account 
psychiatric comorbidities among HIV-HCV coinfected persons. The risk of depression 
induced by HCV therapy is widely recognized [50]. Accordingly, assessment and prompt 
treatment of depressive symptoms before and after treatment initiation [51] should be 
recommended. Continuously assessing the effectiveness of such treatment is of paramount 
importance. While a previous study demonstrated that self-reported fatigue and depression are 
major components of the different dimensions of the quality of life in HIV-HCV coinfected 
patients not receiving anti-HCV treatment [52], our findings underline the importance in 
identifying psychiatric symptoms to help HIV-HCV coinfected patients (on HCV treatment or 
not) to manage multiple therapeutic regimens. Moreover, increasing the range of available 
therapeutic options, including adequate antidepressant treatment, treatment for alcohol and 
cocaine dependence as well as other medications to relieve side-effects, should be considered 
in the early stages of coinfection in order to provide adequate care to the different profiles of 
this vulnerable population.  
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Table 1. Baseline characteristics of the sample used for the analyses, n=727. 
 
 Number of patients (%) Median [IQR]      
Female gender 224 (31)  
Age
a  44[41-48] 
Being employed  371 (51)  
Having children 236 (33)  
High school certificate 195 (27)  
Living in a couple 345 (47)  
Comfortable housing 603 (83)  
Owner or tenant of her/his home 579 (80)  
HIV transmission group  
- injecting drug use (IDU) 
- men who have sex with men (MSM) 
- heterosexual 
- “don’t know” or “other” 
 
472 (65) 
85 (12) 
100 (14) 
70 (9) 
 
Daily cannabis use
b
 105 (14)  
Hazardous alcohol consumption
c 
251 (35)  
Cocaine use
b
 61 (8)  
Heroin use
b
 19 (3)  
CDC stage C 221 (30)  
CD4 cell count  449 [302-648] 
HIV undetectable viral load (<50 copies/ml) 533 (73)  
Severe fibrosis 219 (30)  
a
 Per 10-year increase 
b
 during the previous month 
c
 AUDIT-C score≥4 for men and ≥3 for women 
Table 2. Factors associated with non-adherence to HAART: mixed logistic model, univariate and 
multivariate analysis (1190 visits, 727 patients) 
   Univariate analysis Multivariate analysis 
 Number of 
visits (%) 
or median 
[IQR] 
Number 
of 
patients 
OR [95%CI] p-
value 
aOR [95%CI] p-
value 
Female gender 363 (31) 224 0.94 [0.58-1.51] 0.80   
Age
a 
45 [42-48]  0.76 [0.54-1.09] 0.14   
Being employed 581 (50) 387 0.71 [0.47-1.08] 0.11   
Having children 366 (31) 247 0.99 [0.62-1.57] 0.96   
High school certificate 321 (31) 185 0.73 [0.43-1.23] 0.24   
Living in a couple 567 (48) 368 0.69 [0.45-1.06] 0.09   
Comfortable housing 994 (84) 630 0.47 [0.25-0.80] 0.005   
Owner or tenant of 
her/his home 
 
966 (82) 
 
604 
 
0.89 [0.52-1.50] 
 
0.65 
  
Depressive symptoms 
(DS)
b
 and 
antidepressant 
treatment (ADT) 
- no DS/no ADT (ref) 
- no DS/ADT 
- DS/no ADT 
- DS/ADT 
 
 
 
 
617 (52) 
89 (7) 
312 (26) 
172 (14) 
 
 
 
 
421 
76 
238 
136 
 
 
 
 
1 
1.30 [0.62-2.70] 
1.63 [1.04-2.57] 
2.02 [1.15-3.58] 
 
 
 
 
 
0.49 
0.03 
0.02 
 
 
 
 
1 
1.31 [0.64-2.71] 
1.63 [1.04-2.54] 
1.83 [1.05-3.22] 
 
 
 
 
 
0.46 
0.03 
0.03 
Hazardous alcohol 
consumption
c 
 
397 (33) 
 
286 
 
2.26 [1.49-3.42] 
 
<10
-3 
 
1.91 [1.27-2.87] 
 
0.002 
Heroin use
d
 32 (3) 25 3.79 [1.19-12.05] 0.02   
Cocaine use
d
 98 (8) 78 2.85 [1.43-5.67] 0.003 2.26 [1.15-4.43] 0.02 
Number of years since 
HAART initiation
 e 
 
3 [1-5] 
  
0.87 [0.59-1.27] 
 
0.46 
  
CDC stage C 354 (30) 223 0.68 [0.42-1.09] 0.11   
HCV treated 88 (7)  0.33 [0.15-0.75] 0.008 0.38 [0.17-0.84] 0.02 
Number of HAART 
pills per day 
 
4 [3-6] 
  
1.01 [0.92-1.09] 
 
0.90 
  
Number of symptoms
*
 9 [4-14]  1.05 [1.02-1.08] 0.002 - - 
Daily cannabis use
*
 171 (16) 125 2.21 [1.21-4.06] 0.01 - - 
a
 Per 10-year increase 
b
 CES-D score>17 for men and >23 for women 
c
 AUDIT-C score≥4 for men and ≥3 for women 
d
 during the previous month 
e
 Per 5-year increase 
* 
not included in the multivariate model
Table 3. Association between depressive symptoms variable and number of symptoms: mixed linear 
model. 
 
 Coeff [95%CI] p-value 
Depressive symptoms
a
 and 
antidepressant treatment 
- no DS/no ADT (ref) 
- no DS/ADT 
- DS/no ADT 
- DS/ADT 
 
 
1 
1.93 [0.66-3.21] 
5.45 [4.66-6.25] 
5.68 [4.66-6.70] 
 
 
 
0.003 
<10
-3 
<10
-3 
Y=number of perceived symptoms  
a 
CES-D score>17 for men and >23 for women 
 
 
Table 4. Association between “depressive symptoms and antidepressant treatment” variable and daily 
cannabis use: mixed logistic model 
 
 OR [95%CI] p-value 
Depressive symptoms
a
 and 
antidepressant treatment 
- no DS/no ADT (ref) 
- no DS/ADT 
- DS/no ADT 
- DS/ADT 
 
 
1 
1.41 [0.44-4.53] 
0.96 [0.45-2.08] 
2.65 [1.05-6.70] 
 
 
 
0.57 
0.93 
0.04 
Y=daily cannabis use 
a 
CES-D score>17 for men and >23 for women 
 
 
